Effects of Cu(II) (3,5-diisopropylsalicylate)2 on soluble protein kinase C activity in rat liver

Cancer Lett. 1989 Oct;47(3):169-77. doi: 10.1016/0304-3835(89)90087-6.

Abstract

The superoxide dismutase mimetic compound, Cu(II) (3,5-diisopropylsalicylate)2 (CuDIPS) inhibited soluble Ca2+/phospholipid dependent protein, kinase (protein kinase C) in rat liver, competing with ATP. The Ca2+/phospholipid- and TPA-stimulated phosphorylation of endogenous proteins were also inhibited by CuDIPS. In vitro and in vivo CuDIPS as well as CuSO4 reduced the activity of TPA-stimulated protein kinase C, while 3,5-diisopropylsalicylate lacked this effect. Our results indicate that CuDIPS interacts with the catalytic domain of the enzyme and the inhibition of protein kinase C may be due to copper(II) ions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / pharmacology
  • Animals
  • Calcium / pharmacology
  • Cytosol / drug effects
  • Dose-Response Relationship, Drug
  • Liver / drug effects*
  • Liver / enzymology
  • Male
  • Phosphatidylserines / pharmacology
  • Phosphorylation
  • Protein Kinase C / metabolism*
  • Proteins / metabolism
  • Rats
  • Rats, Inbred Strains
  • Salicylates / pharmacology*
  • Tetradecanoylphorbol Acetate / pharmacology

Substances

  • Phosphatidylserines
  • Proteins
  • Salicylates
  • copper bis(3,5-diisopropylsalicylate)
  • Adenosine Triphosphate
  • Protein Kinase C
  • Tetradecanoylphorbol Acetate
  • Calcium